In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pearl Therapeutics Inc.

Division of AstraZeneca PLC
www.pearltherapeutics.com

Latest From Pearl Therapeutics Inc.

Coming Together On Pre-Cert: Digital Health World Engages With FDA To Hash Out Regulatory Future

US FDA, industry and other digital health stakeholders huddled at the National Institutes of Health for two days of deep discussions around how the Pre-Certification Pilot was advancing, and how the agency should implement a program that emphasizes certifying "excellence" in company processes. Check out coverage of the meeting and Medtech Insight's exclusive podcast interview with FDA project lead Bakul Patel.

Digital Health Regulation

Win For AZ's COPD Triple Combo In Bid To Catch GSK

GlaxoSmithKline is streets ahead in the three-in-one COPD market, having received approval last year in the USA and Europe for Trelegy Ellipta, but AstraZeneca's PT010 may provide competition in the future having met six out of seven lung function primary endpoints in a Phase III trial.

Clinical Trials Respiratory

2018 An Inflection Point For mHealth After An Active Year

The past year saw US FDA and industry work hard and fast to prepare for what looks like an inevitable boom in the digital-health sector. According to interviews, the time is ripe for adoption of mobile health apps to help reduce health-care costs, but the brave new world also brings with it big challenges.

Digital Health Analysis

Five Takeaways From Commissioner Gottlieb's Talk At The National Press Club

Among the topics US FDA Commissioner Gottlieb touched on were the agency's efforts to reduce clinical development burdens, improve information-sharing and comply with President Trump's two-for-one regulations order.

Regulation FDA
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
  • Therapeutic Areas
  • Inflammation
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • AstraZeneca PLC
  • Senior Management
  • Charles Bramlage, Pres. & CEO
    Sarvajna Dwivedi, PhD, CSO
    Colin Reisner, MD, EVP, Clin. Dev. & Med. Affairs & CMO
    William Picht, Jr., VP, Fin. & Admin.
  • Contact Info
  • Pearl Therapeutics Inc.
    Phone: (650) 305-2600
    200 Saginaw Dr.
    Redwood City, CA 94063
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register